Related Experiment Videos
Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment
Michael W J Boehme1, Ino K Gao, Cornelia Norden
1Dep. of Internal Medicine IV, University of Heidelberg, Bergheimer Str. 58, D-69115 Heidelberg, Germany. m.boehme@lrabb.de
Rheumatology International
|February 9, 2005
Summary
Oral iloprost therapy in rheumatoid arthritis patients reduced key markers of inflammation and endothelial cell activation. These anti-inflammatory effects, including decreased adhesion molecules and thrombomodulin, suggest potential clinical benefits and endothelial stabilization.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by proinflammatory cytokines.
- Iloprost, a prostacyclin analogue, has demonstrated in vitro and in vivo anti-inflammatory properties by reducing cytokine release.
- Endothelial cell activation and injury are implicated in RA pathogenesis, indicated by adhesion molecules and thrombomodulin levels.
Purpose of the Study:
- To investigate the anti-inflammatory effects of oral iloprost in RA patients.
- To assess iloprost's impact on plasma adhesion molecules (VCAM-1, E-selectin, ICAM-1) as markers of endothelial activation.
- To evaluate iloprost's effect on plasma thrombomodulin as an indicator of endothelial cell injury.
Main Methods:
- 14 active RA patients received oral iloprost for 7 days.
- Plasma levels of VCAM-1, E-selectin, ICAM-1, and thrombomodulin were measured via ELISA.
- Disease activity (DAS) and pain were assessed and correlated with biomarker changes.
Main Results:
- Oral iloprost significantly decreased plasma levels of VCAM-1, ICAM-1, E-selectin, and thrombomodulin.
- Reductions ranged from -20.1% to -24.6% after 7 days of therapy (p ≤ 0.008).
- Decreased levels of VCAM-1 and ICAM-1 persisted for one week post-therapy, with significant correlations found between clinical disease activity and biomarker levels.
Conclusions:
- Oral iloprost therapy shows potential clinical effects in RA patients.
- Decreased adhesion molecules suggest an immunomodulatory effect of iloprost.
- Reduced thrombomodulin levels may indicate iloprost stabilizes endothelial cell function by reducing injury.